drugset / Trial / NCT01740271

A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients

NCT01740271 ↗

Phase 2 Unknown 48 enrolled AHS Cancer Control Alberta
NaSingle-groupOpen-labelTreatment

Summary

Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most accurate way. The purpose of this study is to see if epirubicin dosing based on people's genetic profiles is better than the usual methods.

Timeline

Start
2012-12
Primary completion
2015-06
Completion
2025-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule — —

Indications